Weight loss drug, 710GO, demonstrates efficacy in animal studies without GLP-1 side effects

Endevica Bio’s studies show the drug is safe and effective in obese monkeys and rats. 

“Endevica Bio is a disruptive force in a multibillion-dollar market championing the fight against one of America’s most
pressing health crises.”

Russell Pottereld, CEO – Endevica Bio

Market Opportunity

Obesity affects over 100 million adults in the U.S., creating significant economic and health burdens, including $173 billion in annual medical expenditure costs. This epidemic continues to drive life-threatening health risks for heart disease, type 2 diabetes, and cancer, with over half of obese adults experiencing high blood pressure. Despite advances, existing treatments like GLP-1 agonists face challenges such as high cost, intolerability, and weight regain after discontinuation, leaving a gap in long-term solutions.

Obese Adults in
the US
Annual medical
expenditures
of US Healthcare
Spending

The obesity treatment market is expansive, underserved, and evolving rapidly. GLP-1 agonists have proven the demand for an effective solution is high, but critical gaps in efficacy, cost, and sustainability limit real improvement. Endevica Bio addresses these challenges, offering a superior alternative with a safer, more effective, and enduring solution. As an oral medication, it will be more affordable and readily accepted by patients unwilling to utilize injectables. Endevica Bio is a disruptive force in a multibillion-dollar market championing the fight against one of America’s most pressing health crises.

Endevica Bio envisions a healthier world through
innovative, sustainable solutions for obesity.

Human Impact

Endevica Bio is developing an obesity treatment designed to transform the weight loss industry through highly effective, safer, and less costly solutions than current GLP-1s. Our groundbreaking approach includes the development of melanocortin-4 receptor agonists. Our lead candidate, 710GO, represents a pivotal shift in weight loss treatment.

1

Effective Weight Loss

Achieved 7.5% weight loss in 5 weeks in primate models of diet-induced obesity, on par with GLP-1s.

2

No Weight Regain

Unlike GLP-1s, 710GO shows no rebound weight gain after discontinuation in animal studies.

3

Superior Safety Profile

A cardiac-safe molecule with exceptionally clean safety signals, addressing patient tolerability concerns.

4

Optimized Combinations

Combines with semaglutide for enhanced results and reduced GLP-1 doses.

5

Accessible

With an oral-dosage format, weight loss treatments are more accessible, tolerable, and affordable.

Poised for Growth, Clear Milestones Ahead

END OF MAY 2025

Completion of IND-enabling nonclinical studies

Q3 2025

710GO Phase 1 begins

1H 2026

710GO Phase 1B readout